{"filings":[{"id":650437,"accession_number":"0000926617-26-000037","cik":926617,"company_name":"Aspira Women's Health Inc.","ticker":"AWHL","form_type":"8-K","filed_at":"2026-05-26T13:03:51+00:00","items":["1.01","9.01"],"status":"ready","headline":"Aspira Women's Health enters collaboration with Cleveland Clinic for AI-powered diagnostics","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Partnering fee of $125,000; $50,000 due within 30 days, then $25,000 on each of first three anniversaries.","Collaboration focuses on biomarker discovery, AI-driven modeling, and clinical validation for women's health diagnostics.","Joint leadership: Dr. Kevin Elias (Cleveland Clinic) and Dr. Todd Pappas (Aspira) will lead multidisciplinary teams.","Initial five-year term; may be extended by mutual agreement; either party can terminate with 60 days' notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":16530000.000000002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99841,"accession_number":"0000926617-26-000029","cik":926617,"company_name":"Aspira Women's Health Inc.","ticker":"AWHL","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Aspira Women's Health appoints John Strahley as CFO; Brian Hungerford departs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brian Hungerford's consulting agreement terminated at his request effective April 26, 2026, for personal reasons.","John Strahley appointed CFO and CAO effective April 27, 2026; fractional role requiring minimum 20 hours per week.","Strahley receives annual base salary of $167,000 and grant of 70,000 stock options; 25% vest after 90 days.","Strahley previously served as CFO of IsoPlexis and Managing Director at Ironwood Capital; began career as CPA.","No severance or post-termination benefits beyond accrued obligations; employment at-will."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":16530000.000000002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116093,"accession_number":"0000926617-26-000012","cik":926617,"company_name":"Aspira Women's Health Inc.","ticker":"AWHL","form_type":"8-K/A","filed_at":"2026-03-25T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Aspira enters lab services pact with Mayo Clinic for Ova1Plus and OvaWatch tests","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Agreement effective Dec 16, 2025; Mayo will list Aspira’s Ova1Plus and OvaWatch in its test catalog.","Mayo obligated to set minimum list prices (redacted); will market tests to its clients.","Initial term (redacted years) with automatic renewal; either party may terminate without cause on (redacted) days notice.","Testing is non-exclusive and on an as-requested basis; many financial terms remain confidential.","Partnership leverages Mayo’s national distribution to expand reach of Aspira’s ovarian cancer tests."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":16530000.000000002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116094,"accession_number":"0000926617-26-000007","cik":926617,"company_name":"Aspira Women's Health Inc.","ticker":"AWHL","form_type":"8-K","filed_at":"2026-01-30T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Aspira Women's Health enters $1.05M subordinated loan with Agile Lending, maturing Aug 2026","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Principal of $1,050,000 plus $441,000 interest due; matures August 26, 2026.","Loan subordinated to all Senior Indebtedness; secured by substantially all assets.","Proceeds used for general corporate purposes; $50,000 administrative agent fee.","Financial covenants partially waived; financing statement only filed upon default.","Agile Lending LLC as lead lender; Agile Capital Funding LLC as collateral agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":16530000.000000002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132536,"accession_number":"0000926617-25-000014","cik":926617,"company_name":"Aspira Women's Health Inc.","ticker":"AWHL","form_type":"8-K","filed_at":"2025-12-31T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aspira Women's Health publishes investor presentation on its website on December 29, 2025","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["No specific financial or strategic updates identifiable from the limited presentation text provided.","The filing only confirms the posting of a slide deck; content of the deck was not detailed.","Investors should review the full presentation at the company's IR page for any material information."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":16530000.000000002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132535,"accession_number":"0001104659-25-124245","cik":926617,"company_name":"Aspira Women's Health Inc.","ticker":"AWHL","form_type":"8-K","filed_at":"2025-12-23T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Aspira Women's Health enters $10M equity line with Lincoln Park Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lincoln Park committed to purchase up to $10M of Aspira common stock at company's discretion over 24 months.","Purchase price set at 95% of the lower of same-day lowest sale price or average of three lowest closing prices over prior 10 days.","Regular purchases: up to 50k-100k shares/day, capped at $500k per purchase; accelerated purchases allowed.","Commitment shares issued: 3% of $10M commitment ($300k worth) as consideration to Lincoln Park.","Company may terminate agreement at any time with one business day notice; Lincoln Park prohibited from short selling."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":16530000.000000002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132534,"accession_number":"0000926617-25-000010","cik":926617,"company_name":"Aspira Women's Health Inc.","ticker":"AWHL","form_type":"8-K","filed_at":"2025-12-22T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Aspira Women's Health signs 5-year lab services pact with Mayo Clinic","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Aspira will provide Ova1Plus and OvaWatch tests to Mayo on a non-exclusive, as-requested basis for clinical purposes.","Initial term of 5 years, automatic annual renewals; either party may terminate with 90 days' notice.","Mayo to list tests in its catalog, handle ordering, results delivery, and billing; Aspira invoices Mayo.","Fees fixed during initial term absent mutual adjustment; agreement not yet filed due to redactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":16530000.000000002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132533,"accession_number":"0000926617-25-000004","cik":926617,"company_name":"Aspira Women's Health Inc.","ticker":"AWHL","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aspira Women's Health Q3 revenue flat at $2.3M; gross margin expands to 64.1%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Nine-month gross profit $4.5M (+12.2% YoY); margin 64.1% vs 58.4%.","Operating expenses down 34% to $11.1M; cash burn reduced 54.5% to $5.0M.","Average unit price per test +7% YoY; sales per FTE up 167% in Q3.","Shift to profitable revenue; OvaSuite adopted by large IDN for O-RADS 4 patients.","Progress on ENDOinform endometriosis diagnostic; milestones toward commercial readiness."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":311000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":16530000.000000002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132531,"accession_number":"0001104659-25-105561","cik":926617,"company_name":"Aspira Women's Health Inc.","ticker":"AWHL","form_type":"8-K/A","filed_at":"2025-11-03T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Aspira Women's Health amends 8-K to correct warrant termination date","summary_kind":"llm","event_type":"other","confidence":"medium","bullets":["Filing corrects termination date in Series A Common Stock Warrants disclosed on Sept 25, 2025.","Corrected form of warrant attached as Exhibit 4.1.","No other changes to the prior agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":16530000.000000002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132532,"accession_number":"0001493152-25-018146","cik":926617,"company_name":"Aspira Women's Health Inc.","ticker":"AWHL","form_type":"8-K","filed_at":"2025-10-15T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Aspira Women's Health upgrades to OTCQX from OTCQB effective Oct 14, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upgraded from OTCQB Venture Market to OTCQX Best Market on October 14, 2025.","Common stock trades under ticker 'AWHL' on OTCQX.","The upgrade reflects company's eligibility for higher OTC Markets tier."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":16530000.000000002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149068,"accession_number":"0001493152-25-014925","cik":926617,"company_name":"Aspira Women's Health Inc.","ticker":"AWHL","form_type":"8-K","filed_at":"2025-09-25T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Aspira Women's Health amends securities purchase agreement; grants board seats, fixes warrant exercise price at $0.35","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment requires Aspira to file Form S-1 by Sept 30, 2025 to register shares and warrant shares.","Purchasers (existing accredited shareholders) gain right to appoint 3 directors until earlier of 3 years or 50% warrant threshold.","Warrants amended: fixed exercise price $0.35, cash-only exercise, 6-year term, exercisable after 6 months.","Exempt Issuance definition modified to exclude firm commitment or at-the-market offerings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":16530000.000000002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149067,"accession_number":"0001493152-25-013987","cik":926617,"company_name":"Aspira Women's Health Inc.","ticker":"AWHL","form_type":"8-K","filed_at":"2025-09-18T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Aspira Women's Health raises $3.06M in private placement at $0.45/unit, issues 6.55M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds $2.95M from sale of 6.55M shares and 4.91M warrants at $0.45/unit; plus $112.5K from exercise of 450K warrants.","Each unit: 1 share + 0.75 warrant; warrants exercisable at $0.75/share for 5 years.","Net proceeds used for working capital, commercial activities, and general corporate purposes.","Board members participated as investors alongside existing and new accredited investors.","Total new shares issued ~7.0M; warrant overhang 4.91M shares at $0.75 exercise price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":16530000.000000002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149066,"accession_number":"0001641172-25-026441","cik":926617,"company_name":"Aspira Women's Health Inc.","ticker":"AWHL","form_type":"8-K","filed_at":"2025-09-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Aspira Women's Health appoints Brian Hungerford as CFO, $300K salary, 100K options","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brian Hungerford appointed CFO and Principal Accounting Officer, effective September 2, 2025, replacing Julie Carrillo.","Annual salary of $300,000, eligible for 35% cash bonus at management discretion based on performance goals.","Stock option grant of 100,000 shares; 25% vest on Sept 2, 2026, remainder vests monthly over 36 months.","Severance: if terminated without cause after 6-12 months, 3 months salary; after 12 months, 6 months salary.","Consulting arrangement via Hungerford Consulting LLC; company to indemnify and provide D&O coverage."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":16530000.000000002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149065,"accession_number":"0001493152-25-011867","cik":926617,"company_name":"Aspira Women's Health Inc.","ticker":"AWHL","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aspira Women's Health Q2 revenue stable at $2.4M; H1 gross margin improves to 66.1%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 product revenue $2.404M vs $2.423M YoY; commercial portfolio AUP up 12%.","H1 2025 revenue $4.683M (+2.3% YoY); gross margin 66.1% (vs 57.6% in H1 2024).","Operating expenses down 31% to $8.1M; cash burn reduced 41% to $4.8M in H1.","Sales force cut from 19 to 7 FTEs; sales per FTE up 156% in Q2.","CEO Mike Buhle reaffirms ENDOInform milestone completion by end of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":222000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":16530000.000000002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149064,"accession_number":"0001493152-25-011246","cik":926617,"company_name":"Aspira Women's Health Inc.","ticker":"AWHL","form_type":"8-K","filed_at":"2025-07-15T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Aspira Women's Health appoints Jane Pine Wood to board effective July 11, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jane Pine Wood appointed as director, effective July 11, 2025.","Wood has over 38 years of experience as an attorney for laboratories and healthcare providers.","She currently serves as Counsel at McDonald Hopkins; previously Chief Legal Counsel at BioReference Health.","No family relationships or related-party transactions with the company; no arrangement with any person for appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":16530000.000000002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168041,"accession_number":"0001641172-25-014701","cik":926617,"company_name":"Aspira Women's Health Inc.","ticker":"AWHL","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aspira Women's Health says ARPA-H terminated $10M ENDOinform contract after receiving $3.5M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ARPA-H terminated $10M contract for ENDOinform test on June 9, 2025, citing unmet Milestone 3 specs.","Aspira had received $2M and $1.5M milestone payments (Nov 2024, Mar 2025) totaling $3.5M.","Company disputes termination, claims it met all Milestone 3 requirements and was progressing on Milestone 4.","CEO says R&D team will continue ENDOinform development targeting 2026 completion with shareholder and partner support.","Contract termination may accelerate development pace due to reduced administrative burden."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":16530000.000000002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168040,"accession_number":"0001641172-25-013604","cik":926617,"company_name":"Aspira Women's Health Inc.","ticker":"AWHL","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Aspira Women's Health 2025 annual meeting results: all proposals approved","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All six director nominees elected with over 96% of votes cast in favor.","Say-on-pay advisory vote passed: 6.9M for, 2.0M against (~76% of votes cast).","Warrant issuance to related parties for 27,778 shares approved (~83% of votes cast).","Amendment to 2019 Stock Incentive Plan to add 2.5M shares (total 4.53M) approved (~96%).","Ratification of BDO USA as auditor for FY2025 approved (~98% of votes cast)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":16530000.000000002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168039,"accession_number":"0001641172-25-011391","cik":926617,"company_name":"Aspira Women's Health Inc.","ticker":"AWHL","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aspira Q1 revenue up 5.9% to $2.28M; gross margin 68.5%, cash burn reduced 30%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2.28M vs $2.15M YoY (+5.9%), driven by select price increases and 94% jump in sales per FTE.","Gross profit $1.6M (+28.5%); gross margin improved to 68.5% from 56.4% due to one-time accrual reduction and OvaWatch profitability.","Operating expenses fell 19% to $4.8M (vs $5.9M); operating cash burn reduced 30% to $3.1M.","Cash on hand rose to $3.3M from $1.8M; current liabilities decreased 30% to $3.8M.","CEO Mike Buhle cited early traction under new leadership; ENDOInform R&D updates expected by end of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":16530000.000000002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168038,"accession_number":"0001641172-25-005086","cik":926617,"company_name":"Aspira Women's Health Inc.","ticker":"AWHL","form_type":"8-K","filed_at":"2025-04-16T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Aspira Women's Health receives Nasdaq delisting notice for failure to meet equity minimum","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received written notice on April 15, 2025 that Nasdaq Hearings Panel determined to delist shares due to non-compliance with Listing Rule 5550(b)(1).","Company failed to maintain minimum $2.5 million in stockholders' equity for continued listing on Nasdaq Capital Market.","Trading suspension on Nasdaq effective at open of trading on April 17, 2025.","Common stock expected to begin trading on OTC Markets under symbol AWH following suspension."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":16530000.000000002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168037,"accession_number":"0001641172-25-003135","cik":926617,"company_name":"Aspira Women's Health Inc.","ticker":"AWHL","form_type":"8-K","filed_at":"2025-04-08T23:59:59+00:00","items":["1.01","3.02","5.02","8.01","9.01"],"status":"ready","headline":"Aspira Women's Health raises up to $2M via discounted equity; appoints three new directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Equity purchase agreement with Triton Funds for up to $2M; first tranche 354,988 shares for $25,000.","Subsequent purchases priced at 75% of lowest 5-day trading price before closing.","Proceeds for commercial activities and working capital; subject to Nasdaq 19.99% limitation.","Appointed new directors: Dr. Jeffrey Cohen, John Fraser, Cynthia Hundorfean (eff. Apr 2-6, 2025).","Julie Carrillo appointed interim Principal Accounting Officer; Dr. Celeste Fralick departed Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":16530000.000000002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185272,"accession_number":"0001641172-25-001708","cik":926617,"company_name":"Aspira Women's Health Inc.","ticker":"AWHL","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Aspira Women's Health amends bylaws, reduces stockholder meeting quorum to one-third","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved amendment to Bylaws on March 28, 2025, reducing quorum to 33.33% of outstanding shares.","Change aims to improve ability to hold stockholder meetings when called.","Full text of amendment filed as Exhibit 3.1 to this Form 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":16530000.000000002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185271,"accession_number":"0001641172-25-001703","cik":926617,"company_name":"Aspira Women's Health Inc.","ticker":"AWHL","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Aspira Women's Health enters new CEO employment agreement; $400k salary, 100k option grant","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Base salary $400,000 with target bonus up to 50% based on corporate goals.","Stock option award of 100,000 shares, vesting monthly over four years.","Severance: after 6 months, 3 months base; after 12 months, 6 months base; plus COBRA.","Change of control triggers full vesting of unvested options.","Non-solicitation covenant for 12 months post-termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":16530000.000000002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185270,"accession_number":"0001641172-25-000923","cik":926617,"company_name":"Aspira Women's Health Inc.","ticker":"AWHL","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aspira Women's Health Q4 product revenue up 9.5% to $2.3M; FY revenue flat at $9.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 product revenue $2.3M (+9.5% YoY); OvaSuite tests ~6,004 (+6.1%); AUP $391 (+4.3%); gross margin 63.4% (+6.2 ppts).","FY product revenue $9.2M (flat YoY); tests ~24,305 (+1.3%); AUP $378 (-1.0%); gross margin 59.7% (+2.2 ppts).","Operating expenses Q4 $4.9M (-8% YoY); FY $21.8M (-10% YoY).","Cash ~$3.7M as of Mar 27, 2025; pending $1.5M ARPA-H milestone; raised $5.75M via convertible notes and ATM.","New CEO Mike Buhle appointed; ARPA-H $10M award milestone; Ellen Beausang added to Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":16530000.000000002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185269,"accession_number":"0001641172-25-000587","cik":926617,"company_name":"Aspira Women's Health Inc.","ticker":"AWHL","form_type":"8-K","filed_at":"2025-03-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Aspira Women’s Health VP of Finance James Crawford resigns effective April 4, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James Crawford informed CEO Mike Buhle of his resignation as VP of Finance on March 21, 2025.","Resignation is for personal reasons and effective April 4, 2025.","No replacement has been announced as of the filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":16530000.000000002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185268,"accession_number":"0001493152-25-010933","cik":926617,"company_name":"Aspira Women's Health Inc.","ticker":"AWHL","form_type":"8-K","filed_at":"2025-03-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Celeste Fralick resigns from Aspira Women's Health board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Celeste Fralick resigned as director for personal reasons, effective March 31, 2025.","No replacement has been announced; board size will decrease by one.","Resignation communicated on March 15, 2025; filing made March 19, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":16530000.000000002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185267,"accession_number":"0001493152-25-009784","cik":926617,"company_name":"Aspira Women's Health Inc.","ticker":"AWHL","form_type":"8-K","filed_at":"2025-03-11T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Aspira Women's Health closes $1.37M private placement of convertible notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $1.37M principal amount of Senior Secured Convertible Notes due March 2030.","Notes convertible into units of one share plus 2.25 warrants at $0.25 per unit.","Warrants exercisable at $0.25/share for first 24 months, then $0.50 for five years.","Company may force conversion if aggregate proceeds from this and future sales exceed $4M.","Net proceeds to support commercial activities, general corporate purposes and working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":16530000.000000002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185266,"accession_number":"0001493152-25-006890","cik":926617,"company_name":"Aspira Women's Health Inc.","ticker":"AWHL","form_type":"8-K","filed_at":"2025-02-14T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Aspira Women's Health resolves Nasdaq listing violation by amending warrants; compliance regained but risk remains","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice Feb 11, 2025 for violating Rule 5635(c) by issuing shares/warrants below market value without shareholder approval.","Amended warrants same day to prohibit exercise until shareholder approval, regaining compliance with Nasdaq.","Private placement involved 1,264,739 shares and warrants at $1.53/unit; market value per unit was $1.595.","Company cautions there is no guarantee its common stock will remain listed on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":16530000.000000002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185265,"accession_number":"0001493152-25-005666","cik":926617,"company_name":"Aspira Women's Health Inc.","ticker":"AWHL","form_type":"8-K","filed_at":"2025-02-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Aspira Women's Health President resigns; appoints new director Ellen Beausang","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Sandra Milligan resigns as President effective Feb 21, 2025, for personal reasons.","Duties assumed by Jamie Sullivan (Chief of Staff) and Todd Pappas (VP R&D and Lab Ops).","Ellen Beausang appointed to board; she is President/Chief Commercial Officer of BioReference Health (since June 2022).","Beausang brings 25+ years experience from Pfizer, Thermo Fisher, Quest Diagnostics; no arrangement or related-party transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":16530000.000000002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185264,"accession_number":"0001493152-25-004329","cik":926617,"company_name":"Aspira Women's Health Inc.","ticker":"AWHL","form_type":"8-K","filed_at":"2025-01-31T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Aspira Women's Health appoints Michael Buhle as CEO, James Crawford as VP of Finance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Buhle appointed CEO, adds role to current Chief Commercial Officer duties; effective Jan 28, 2025.","James Crawford appointed VP of Finance, serving as principal financial and accounting officer; joined Aspira in 2021.","Interim CEO Dr. Sandra Milligan remains President of the Company.","No family relationships or material interests with existing directors or officers per Regulation S-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":16530000.000000002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185263,"accession_number":"0001493152-25-001860","cik":926617,"company_name":"Aspira Women's Health Inc.","ticker":"AWHL","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aspira Women's Health files 8-K with investor presentation; no specifics in text","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Investor presentation furnished as Exhibit 99.1 for January 13, 2025 meeting.","Filing text does not contain any financial results or material updates.","Exhibit content not included in provided filing excerpt; unable to summarize."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":16530000.000000002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185262,"accession_number":"0001493152-25-001214","cik":926617,"company_name":"Aspira Women's Health Inc.","ticker":"AWHL","form_type":"8-K","filed_at":"2025-01-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Aspira Women's Health interim CFO John Kallassy resigns; CEO becomes principal accounting officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John Kallassy resigned as Interim CFO effective January 10, 2025, for personal reasons.","CEO Dr. Sandra Milligan will serve as principal accounting officer until a permanent CFO is appointed.","Board reinstated Dr. Milligan's full salary retroactive to December 16, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":16530000.000000002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201857,"accession_number":"0001493152-24-052755","cik":926617,"company_name":"Aspira Women's Health Inc.","ticker":"AWHL","form_type":"8-K","filed_at":"2024-12-31T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Aspira Women's Health receives Nasdaq delisting notice for MVLS non-compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Notice received Dec 31, 2024; company failed to regain $35M MVLS requirement by Dec 30, 2024 deadline.","Unless appeal requested by Jan 7, 2025 with $20,000 fee, common stock delisted Jan 10, 2025.","Company intends to appeal; appeal stays delisting pending Nasdaq decision.","No assurance of success; risk of delisting from Nasdaq Capital Market remains."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":16530000.000000002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201856,"accession_number":"0001493152-24-050269","cik":926617,"company_name":"Aspira Women's Health Inc.","ticker":"AWHL","form_type":"8-K","filed_at":"2024-12-16T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Aspira Women's Health CEO Sandford steps down; Dr. Milligan interim CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Nicole Sandford departs immediately for family health matter; remains as consultant for transition.","President Dr. Sandra Milligan named interim CEO; nationwide search for permanent successor underway.","Separation: $375,000 biweekly over 9 months plus $135,000 bonus upon fundraising or by Sept 30, 2025.","Board cites Sandford's role in launching OvaWatch and securing $10M ARPA-H award for endometriosis test."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":16530000.000000002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201855,"accession_number":"0001493152-24-045354","cik":926617,"company_name":"Aspira Women's Health Inc.","ticker":"AWHL","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aspira Women's Health Q3 rev $2.3M, cash burn $2.9M, reaffirms FY 2024 cash guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 OvaSuite revenue $2.3M (+2% YoY); test volume 6,001 units (+4% YoY).","OvaWatch volume grew 27% YoY, now 22% of total test volume.","Cash used in ops $2.9M, down 12% from Q2; FY 2024 cash burn guidance reaffirmed $13.0-14.5M.","Awarded $10M ARPA-H contract for ENDOinform; expects first $2M payment by year-end.","Gross margin 60% (vs 59% YoY); sales & marketing up 26% but G&A down 25%."],"consensus_eps_estimate":-0.2475,"consensus_eps_actual":-0.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":6833000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":16530000.000000002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201854,"accession_number":"0001493152-24-042912","cik":926617,"company_name":"Aspira Women's Health Inc.","ticker":"AWHL","form_type":"8-K","filed_at":"2024-10-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aspira Women's Health presents pipeline status overview; no specific data in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Slide deck provided on October 29, 2024 covers product pipeline but full content is not included in the 8-K.","No financial figures, clinical results, or timeline updates are disclosed in the filing body.","Investors need to refer to the separate slide deck for pipeline details; no material metrics available here."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":16530000.000000002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201853,"accession_number":"0001493152-24-042315","cik":926617,"company_name":"Aspira Women's Health Inc.","ticker":"AWHL","form_type":"8-K","filed_at":"2024-10-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aspira Women's Health awarded $10M ARPA-H grant for endometriosis blood test","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Selected by ARPA-H for Sprint for Women's Health; $10M funding over two years to develop ENDOinform blood test for endometriosis.","First milestone expected Q4 2024; $2M payment upon successful acceptance.","One of only six Launchpad awards among 1,700+ submissions; among largest awards approved.","Virtual Investor Day scheduled for October 29, 2024 at 3:00 p.m. ET.","ENDOinform aims to replace laparoscopic surgery for diagnosing endometriosis, affecting 6M women in US."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":16530000.000000002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201852,"accession_number":"0001493152-24-042202","cik":926617,"company_name":"Aspira Women's Health Inc.","ticker":"AWHL","form_type":"8-K","filed_at":"2024-10-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aspira Women's Health gets $10M ARPA-H award for endometriosis blood test","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Selected by ARPA-H for $10 million in milestone-based funding over two years to develop EndoMDx blood test for endometriosis.","EndoMDx is a multi-marker miRNA blood test intended to aid in detection, currently requiring laparoscopic surgery for diagnosis.","Over 1,700 submissions vied for funding; Aspira will collaborate with ARPA-H Program Manager and Investor Catalyst Hub.","Virtual Investor Day scheduled for October 29, 2024, at 3:00 pm ET to discuss ARPA-H award and pipeline update."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":16530000.000000002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201851,"accession_number":"0001493152-24-041561","cik":926617,"company_name":"Aspira Women's Health Inc.","ticker":"AWHL","form_type":"8-K","filed_at":"2024-10-18T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Aspira Women's Health receives Nasdaq delisting notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Oct 17, 2024 for non-compliance with minimum bid price ($1.00) for 30 consecutive business days.","Has 180 calendar days until April 15, 2025 to regain compliance by closing bid price at $1.00+ for 10 consecutive days.","If not compliant by April 15, may qualify for second 180-day period; else delisting with option to appeal.","Company will monitor and consider options to regain compliance; no assurance of maintaining listing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":16530000.000000002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217886,"accession_number":"0000950170-24-106448","cik":926617,"company_name":"Aspira Women's Health Inc.","ticker":"AWHL","form_type":"8-K","filed_at":"2024-09-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aspira Women's Health (AWH) provides slide deck to investors on Sept 9, 2024; content not disclosed in filing","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Slide deck made available under Item 7.01 Regulation FD Disclosure.","No specific financial, operational, or strategic updates were included in the 8-K text.","Exhibit 99.1 is referenced but full slide content was not appended to this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":16530000.000000002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217885,"accession_number":"0000950170-24-095439","cik":926617,"company_name":"Aspira Women's Health Inc.","ticker":"AWHL","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aspira Women's Health Q2 revenue $2.4M; cuts FY cash guidance to $13-14.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 product revenue $2.4M vs $2.5M YoY; OvaSuite volume 6,471 units (+3%).","Gross margin 59% vs 62% YoY; operating cash used $3.7M in Q2.","Cash at June 30: $1.0M; subsequent raises of $4.0M boosted pro forma cash to $5.0M.","Full-year 2024 cash guidance lowered to $13-14.5M from $15-18M.","OvaWatch volume grew 48% YoY; John Kallassy appointed interim CFO effective Aug 15."],"consensus_eps_estimate":-0.3081,"consensus_eps_actual":-0.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":4576000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":16530000.000000002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217884,"accession_number":"0000950170-24-090145","cik":926617,"company_name":"Aspira Women's Health Inc.","ticker":"AWHL","form_type":"8-K","filed_at":"2024-08-02T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Aspira Women's Health enters $4.45M ATM equity offering with H.C. Wainwright; terminates prior Cantor agreement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATM agreement with H.C. Wainwright to sell up to $4,450,000 of common stock from time to time.","Wainwright receives a 3.0% commission on gross proceeds; Company reimburses certain expenses.","Prior Controlled Equity Offering agreement with Cantor Fitzgerald & Co. terminated on August 2, 2024.","Shares issued under shelf registration statement S-3 (File No. 333-278867) declared effective April 25, 2024.","Company not obligated to sell any shares and may suspend sales at any time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":16530000.000000002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217883,"accession_number":"0000950170-24-088246","cik":926617,"company_name":"Aspira Women's Health Inc.","ticker":"AWHL","form_type":"8-K","filed_at":"2024-07-31T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Aspira Women's Health raises ~$2.14M via warrant inducement; issues new warrants for up to 2.57M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Holder exercises warrants for 1,711,111 shares at reduced $1.25 (down from $4.13) for $2.14M gross proceeds.","Company issues new warrants to purchase up to 2,566,667 shares at $1.36, exercisable for 5 years.","Financial advisory fee of $150k to A.G.P./Alliance Global Partners plus $45k legal expenses and $5k NAE.","Proceeds for general working capital; closing expected by Aug 1, 2024.","Company to file resale registration statement by Aug 30; no variable rate transactions for 6 months post-effectiveness."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":16530000.000000002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217882,"accession_number":"0000950170-24-087276","cik":926617,"company_name":"Aspira Women's Health Inc.","ticker":"AWHL","form_type":"8-K","filed_at":"2024-07-29T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Aspira Women's Health appoints John Ragard to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John Ragard appointed to board effective July 25, 2024; designated by stockholder Jack W. Schuler.","Ragard brings over 46 years of venture capital and public equity investment experience.","Currently Senior Investment Advisor at Wayve Capital; previously managed portfolios at Spouting Rock and Friess Associates.","Will serve as director until the company's 2025 annual meeting of stockholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":16530000.000000002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217881,"accession_number":"0000950170-24-081880","cik":926617,"company_name":"Aspira Women's Health Inc.","ticker":"AWHL","form_type":"8-K","filed_at":"2024-07-05T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Aspira Women's Health receives Nasdaq deficiency notice for market value below $35M","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified AWH that MVLS was below $35M minimum for 30 consecutive business days.","Company has 180 calendar days, until Dec 30, 2024, to regain compliance.","To comply, MVLS must be ≥ $35M for 10 consecutive business days within grace period.","Alternative: increase stockholders' equity to at least $2.5 million.","No immediate delisting; company evaluating options but can't assure listing maintenance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":16530000.000000002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217880,"accession_number":"0000950170-24-080040","cik":926617,"company_name":"Aspira Women's Health Inc.","ticker":"AWHL","form_type":"8-K","filed_at":"2024-07-02T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Aspira Women's Health announces $1.935M private placement of 1.26M shares and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$1.935M from sale of 1,264,739 shares and accompanying warrants at $1.53 per unit.","Warrants exercisable at $2.25 per share for three years from issuance date.","Offering expected to close by July 8, 2024; proceeds for commercial activities and working capital.","Purchasers include existing accredited shareholders and company insiders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":16530000.000000002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237794,"accession_number":"0000950170-24-078612","cik":926617,"company_name":"Aspira Women's Health Inc.","ticker":"AWHL","form_type":"8-K","filed_at":"2024-06-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Aspira Women's Health CFO Torsten Hombeck terminated for cause; CEO interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Torsten Hombeck terminated as CFO on June 27, 2024 due to personal civil matter unrelated to Company.","Termination deemed 'for cause' under employment agreement; no further payments beyond June 28, 2024 salary.","CEO Nicole Sandford assumes CFO duties on interim basis; search for permanent replacement underway.","Separate June 5, 2024 amendment had raised Hombeck's base salary to $375,000 and added Corporate Secretary title."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":16530000.000000002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237793,"accession_number":"0000950170-24-073609","cik":926617,"company_name":"Aspira Women's Health Inc.","ticker":"AWHL","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aspira Women's Health: 26% monthly volume growth, expanded Anthem & Medicaid, lower 2024 cash burn","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["OvaSuite product volume grew >26% in May 2024 vs January 2024; OvaWatch volume YTD up >88% vs 2023.","Anthem contracts expanded to CT, NH, ME, adding 2M lives; total 9M Anthem lives, expects 16M more.","Maryland and Kentucky added OvaWatch to Medicaid fee schedule at $897/test; nine states now cover OvaSuite.","Philippines OvaWatch commercial launch on track for Q3 2024; fee-per-test model expected to yield higher margins.","Company expects to lower 2024 cash used in operations guidance on Q2 2024 earnings call."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":16530000.000000002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237792,"accession_number":"0000950170-24-070892","cik":926617,"company_name":"Aspira Women's Health Inc.","ticker":"AWHL","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Aspira Women's Health appoints CFO Torsten Hombeck as Corporate Secretary, raises base salary to $375k","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Torsten Hombeck appointed Corporate Secretary in addition to CFO role, effective June 1, 2024.","Annual base salary increased to $375,000 from $325,000 (a $50k raise).","Amendment to existing employment agreement entered into on June 6, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":16530000.000000002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237791,"accession_number":"0000950170-24-060049","cik":926617,"company_name":"Aspira Women's Health Inc.","ticker":"AWHL","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aspira Q1 revenue $2.2M; OvaWatch volume up 114% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenue $2.2M, down 4% YoY; OvaSuite volume 5,829 units (-7%).","Gross profit margin improved to 56% from 51% in Q1 2023.","Cash used in operating activities $4.4M, down 22% YoY; 2024 target stays $15-18M.","OvaWatch volume grew 114% YoY; longitudinal monitoring feature launched.","New Anthem Blue Cross CA coverage agreement for OvaSuite effective June 1, 2024."],"consensus_eps_estimate":-0.3358,"consensus_eps_actual":-0.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":2153000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":16530000.000000002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237790,"accession_number":"0000950170-24-059543","cik":926617,"company_name":"Aspira Women's Health Inc.","ticker":"AWHL","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Aspira Women’s Health stockholders approve all proposals at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected six directors (Stefanie Cavanaugh, Celeste R. Fralick, Jannie Herchuk, Lynn O’Connor Vos, Nicole Sandford, Winfred Parnell) with >4.1M votes for each.","Advisory say-on-pay approved: 4,189,574 for, 97,653 against, 1,752 abstain.","Amended 2019 Stock Incentive Plan to increase authorized shares by 1,000,000 (total ISOs up to 3,000,000): 4,187,597 for, 98,942 against.","Ratified BDO P.C. as auditor for FY2024: 7,992,912 for, 88,066 against, 12,358 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":16530000.000000002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2024-05-14T23:59:59+00:00|237790"}